In this ROBO Global Robotics and Automation Index spotlight, we focus on Omnicell Inc (OMCL). The index underlies the $1.13 billion ROBO Global Robotics and Automation ETF (ROBO ). Here, we explore what makes Omnicell unique within the Healthcare Subsector and dive into its recent performance.
Omnicell is a leading provider of medication management solutions. It is revolutionizing pharmacy care delivery through a combination of robotics, smart devices, software, and services. The company designs solutions to help healthcare facilities worldwide improve efficiency, reduce costs, support compliance, and enhance patient safety.
Launched in April 2024, Omnicell’s flagship product — the XT Amplify automated dispensing system — along with other hardware offerings, generates over half of its revenue. These systems also drive recurring revenue through post-installation technical support, software solutions like inventory management, and consumables. By leveraging these avenues, Omnicell aims to increase its recurring revenue to 21% of total revenue by the end of 2024, up from 19% in 2023. According to estimates, Omnicell’s technology could cut nurse medication retrieval time by 54%, reduce time spent by pharmacists on distribution tasks by 75%, and provide access to 97% of limited-distribution drugs.
In Q2, Omnicell reported total revenue of $277 million. This is an increase of $31 million, or 12%, over the previous quarter, but a decrease of 7% year-over-year. The decline was primarily due to macroeconomic factors and the product life cycle of the XT Amplify system. Despite these challenges, the company has exceeded consensus earnings per share (EPS) estimates over the past four quarters.
With a backlog of $1.1 billion, reflecting robust demand for its products, Omnicell serves approximately 80% of all retail pharmacies in the United States. In addition, it holds long-term sole-source agreements with more than half of the top 300 health systems. It also owns an extensive patent portfolio, with over 500 active patents worldwide.
For more news, information, and analysis, visit our Disruptive Technology Channel.
VettaFi LLC (“VettaFi”) is the index provider for ROBO, for which it receives an index licensing fee. However, ROBO is not issued, sponsored, endorsed or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of ROBO.
